ATE383358T1 - 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren - Google Patents
5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitorenInfo
- Publication number
- ATE383358T1 ATE383358T1 AT04717567T AT04717567T ATE383358T1 AT E383358 T1 ATE383358 T1 AT E383358T1 AT 04717567 T AT04717567 T AT 04717567T AT 04717567 T AT04717567 T AT 04717567T AT E383358 T1 ATE383358 T1 AT E383358T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- compounds
- phenylthiazole derivatives
- phenylthiazole
- derivatives
- Prior art date
Links
- ZLLOWHFKKIOINR-UHFFFAOYSA-N 5-phenyl-1,3-thiazole Chemical class S1C=NC=C1C1=CC=CC=C1 ZLLOWHFKKIOINR-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0305152.1A GB0305152D0 (en) | 2003-03-06 | 2003-03-06 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE383358T1 true ATE383358T1 (de) | 2008-01-15 |
Family
ID=9954250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04717567T ATE383358T1 (de) | 2003-03-06 | 2004-03-05 | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8017608B2 (de) |
| EP (1) | EP1608647B1 (de) |
| JP (1) | JP4382085B2 (de) |
| CN (1) | CN100569770C (de) |
| AT (1) | ATE383358T1 (de) |
| AU (1) | AU2004218239B2 (de) |
| BR (1) | BRPI0408068A (de) |
| CA (1) | CA2517708A1 (de) |
| DE (1) | DE602004011199T2 (de) |
| ES (1) | ES2297393T3 (de) |
| GB (1) | GB0305152D0 (de) |
| MX (1) | MXPA05009468A (de) |
| PL (1) | PL1608647T3 (de) |
| PT (1) | PT1608647E (de) |
| WO (1) | WO2004078754A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| CA2607385C (en) * | 2005-05-24 | 2014-12-16 | Laboratoires Serono S.A. | Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases |
| AU2006251157B2 (en) | 2005-05-24 | 2011-09-01 | Merck Serono Sa | Thiazole derivatives and use thereof |
| JP2008543754A (ja) * | 2005-06-09 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | チェックポイントキナーゼの阻害剤 |
| NZ565749A (en) | 2005-08-26 | 2010-12-24 | Serono Lab | Pyrazine derivatives and use as PI3K inhibitors |
| GB2431156A (en) * | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| AU2007206860A1 (en) * | 2006-01-23 | 2007-07-26 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| WO2007129044A1 (en) * | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Thiazole derivatives and their use as anti-tumour agents |
| GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
| AU2007290359B2 (en) * | 2006-09-01 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase |
| GB0620059D0 (en) * | 2006-10-10 | 2006-11-22 | Ucb Sa | Therapeutic agents |
| GB0620818D0 (en) * | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
| US8614215B2 (en) | 2007-02-22 | 2013-12-24 | Merck Serono Sa | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) |
| KR20100031528A (ko) | 2007-06-01 | 2010-03-22 | 더 트러스티즈 오브 프린스턴 유니버시티 | 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료 |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| KR20100093129A (ko) | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체 |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2350067A2 (de) * | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidin-, piperidin- und piperazinderivate und verfahren zu deren anwendung |
| AU2010213014B2 (en) | 2009-02-12 | 2016-02-25 | Merck Serono S.A. | 2-morpholino-pyrido[3,2-d]pyrimidines |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| ES2432671T3 (es) | 2009-07-02 | 2013-12-04 | Novartis Ag | 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K |
| SG10201500895XA (en) * | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
| EA201290305A1 (ru) | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
| SG183155A1 (en) | 2010-02-03 | 2012-09-27 | Signal Pharm Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| RS58326B1 (sr) * | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
| US20130158023A1 (en) | 2011-08-03 | 2013-06-20 | Signal Pharmaceuticals, Llc | Identification of gene expression as a predictive biomarker for lkb1 status |
| CN102633748A (zh) * | 2012-03-22 | 2012-08-15 | 盛世泰科生物医药技术(苏州)有限公司 | 2-甲酸乙酯-5-溴-1,3,4-噻二唑的合成方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| AU2014254059B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer |
| CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| HK1223286A1 (zh) | 2013-05-29 | 2017-07-28 | 西格诺药品有限公司 | 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法 |
| JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US11091472B2 (en) | 2016-02-26 | 2021-08-17 | The Regents Of The University Of California | PI-kinase inhibitors with anti-infective activity |
| UA123558C2 (uk) * | 2016-09-22 | 2021-04-21 | Астразенека Аб | Похідні 5-[2-(піридин-2-іламіно)-1,3-тіазол-5-іл]-2,3-дигідро-1h-ізоіндол-1-ону та їх застосування як подвійних інгібіторів фосфатидилінозитол-3-кіназ дельта і гамма |
| ES2959860T3 (es) | 2017-06-22 | 2024-02-28 | Celgene Corp | Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B |
| EP3941909A4 (de) | 2019-03-21 | 2023-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase-inhibitoren und verfahren zur verwendung davon |
| WO2022017371A1 (zh) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0013899A (pt) * | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
| EP1857443B1 (de) * | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutische Morpholino-substituierte Verbindungen |
| AR038703A1 (es) | 2002-02-28 | 2005-01-26 | Novartis Ag | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 |
-
2003
- 2003-03-06 GB GBGB0305152.1A patent/GB0305152D0/en not_active Ceased
-
2004
- 2004-03-05 US US10/547,691 patent/US8017608B2/en not_active Expired - Fee Related
- 2004-03-05 ES ES04717567T patent/ES2297393T3/es not_active Expired - Lifetime
- 2004-03-05 PT PT04717567T patent/PT1608647E/pt unknown
- 2004-03-05 BR BRPI0408068-8A patent/BRPI0408068A/pt not_active IP Right Cessation
- 2004-03-05 JP JP2006500054A patent/JP4382085B2/ja not_active Expired - Lifetime
- 2004-03-05 AU AU2004218239A patent/AU2004218239B2/en not_active Ceased
- 2004-03-05 MX MXPA05009468A patent/MXPA05009468A/es active IP Right Grant
- 2004-03-05 PL PL04717567T patent/PL1608647T3/pl unknown
- 2004-03-05 CA CA002517708A patent/CA2517708A1/en not_active Abandoned
- 2004-03-05 DE DE602004011199T patent/DE602004011199T2/de not_active Expired - Lifetime
- 2004-03-05 CN CNB2004800117772A patent/CN100569770C/zh not_active Expired - Fee Related
- 2004-03-05 EP EP04717567A patent/EP1608647B1/de not_active Expired - Lifetime
- 2004-03-05 WO PCT/EP2004/002285 patent/WO2004078754A1/en not_active Ceased
- 2004-03-05 AT AT04717567T patent/ATE383358T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0408068A (pt) | 2006-02-14 |
| GB0305152D0 (en) | 2003-04-09 |
| MXPA05009468A (es) | 2006-02-13 |
| EP1608647B1 (de) | 2008-01-09 |
| CN1780832A (zh) | 2006-05-31 |
| DE602004011199D1 (de) | 2008-02-21 |
| DE602004011199T2 (de) | 2009-01-02 |
| WO2004078754A1 (en) | 2004-09-16 |
| EP1608647A1 (de) | 2005-12-28 |
| CA2517708A1 (en) | 2004-09-16 |
| CN100569770C (zh) | 2009-12-16 |
| JP2006515343A (ja) | 2006-05-25 |
| AU2004218239A1 (en) | 2004-09-16 |
| PT1608647E (pt) | 2008-03-27 |
| AU2004218239B2 (en) | 2007-02-22 |
| PL1608647T3 (pl) | 2008-06-30 |
| JP4382085B2 (ja) | 2009-12-09 |
| ES2297393T3 (es) | 2008-05-01 |
| US20060148822A1 (en) | 2006-07-06 |
| US8017608B2 (en) | 2011-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| MY156407A (en) | 5-phenylthiazole derivatives and use as p13 kinase inhibitors | |
| TNSN05278A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
| TW200517386A (en) | Organic compounds | |
| ATE400570T1 (de) | 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs | |
| ECSP055611A (es) | Compuestos miméticos de glucocorticoides, métodos de prepararlos, composiciones farmacéuticas | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| ATE370139T1 (de) | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs | |
| ATE403648T1 (de) | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung | |
| ATE532781T1 (de) | 5-(acylamino)indazol-derivate als kinase- inhibitoren | |
| SE0300480D0 (sv) | Novel compounds | |
| DE602008005326D1 (de) | Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| HRP20050933A2 (en) | Organic compounds | |
| CY1112960T1 (el) | Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων | |
| NO20054340L (no) | Nye sammenkoplede heterocykler og deres anvendelse | |
| ATE546452T1 (de) | Pyrazolopyrrolderivate als proteinkinaseinhibitoren | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| DE602006020295D1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel | |
| EA200501233A1 (ru) | 4-аминопиримидин-5-он | |
| EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
| ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
| ATE445617T1 (de) | Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel | |
| WO2007068473A3 (en) | Organic compounds | |
| SE0202692D0 (sv) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1608647 Country of ref document: EP |